Published 15:02 IST, August 22nd 2020
Pfizer-BioNTech COVID-19 vaccine shows positive response, may seek approval by October
Pfizer-BioNTech to seek approval for their COVID-19 vaccine in October after the early-stage data reveals that it has fewer side effects & favourable immunity.
Advertisement
Pfizer-BioNTech have released the data from the early trials of their COVID-19 vaccine candidate on Thursday. According to this data, their vaccine has shown fewer side effects and a good immune response towards the virus. The pharmaceutical companies are expecting to submit their coronavirus vaccine candidate for approval by October 2020.
Pfizer-BioNTech ahead in COVID-19 vaccine race
US-based Pfizer and Germany based BioNTech SE have been working in collaboration on developing a COVID-19 vaccine. On Thursday, they released the early-stage data from their COVID-19 vaccine trials. As per their official press release, they have decided to move onto phase 2 of their human trials with the second COVID-19 vaccine candidate BNT162b2. This move came after their second vaccine candidate showed favourable immune response with fewer side effects as compared to their first candidate. The BNT162b1 COVID-19 vaccine led to major side effects in people between the age of 18 to 85 years but the BNT162b2 vaccine led to fewer side effects in the 18-55 years age group and no side effects in the 65-85 years old age group.
Today, along with @BioNTech_Group, we shared positive early data on our lead mRNA-based #vaccine candidate (BNT162b2) against #COVID19: https://t.co/P3JfLOQANA $PFE $BNTX pic.twitter.com/YYkMgSzB4Y
— Pfizer Inc. (@pfizer_news) August 21, 2020
“Our selection of the BNT162b2 vaccine candidate and its advancement into a Phase 2/3 study is the culmination of an extensive, collaborative and unprecedented R&D program involving Pfizer, BioNTech, clinical investigators, and study participants with a singular focus of developing a safe and effective COVID-19 RNA vaccine. The Phase 2/3 study protocol follows all the U.S. Food and Drug Administration (FDA) guidance on clinical trial design for COVID-19 vaccine studies,” said Kathrin U. Jansen, Senior Vice President and Head of Vaccine Research & Development of Pfizer as per the press release.
We just shared new key data from our U.S. Phase 1 trial for our lead vaccine candidate against #COVID19#BNT162b2. Our global Ph3 study in up to 30k participants is actively enrolling. Up to date, we have dosed more than 11,000 participants! https://t.co/z9Z7vwJ7st pic.twitter.com/zjOuYcc8sr
— BioNTech SE (@BioNTech_Group) August 21, 2020
According to the press release, Co-Founder of BioNTech Ugur Sahin said, “Today, we are starting our late-stage global study, which will include up to 30,000 participants. We selected BNT162b2 as our lead candidate for this Phase 2/3 trial upon diligent evaluation of the totality of the data generated so far. This decision reflects our primary goal to bring a well-tolerated, highly effective vaccine to the market as quickly as possible, while we will continue to evaluate our other vaccine candidates as part of a differentiated COVID-19 vaccine portfolio."
According to the press release, if the COVID-19 vaccine candidate shows favourable response in phase 2/3 trials, Pfizer-BioNTech may seek emergency approval from the authorities to use the vaccine by October 2020. Their aim is to produce and supply 100 million doses by the end of 2020 and about 1.3 billion doses by the end of 2021 if they receive approval as planned. Pfizer-BioNTech have also signed an agreement with the United States Government to supply them with 600 million doses of the COVID-19 vaccine provided they receive a regular or an emergency approval from the US FDA.
Today’s announcement that the @US_FDA granted Fast Track designation for two of our leading #COVID19 #vaccine candidates signifies an important milestone in our efforts: https://t.co/wH48BUPpCj pic.twitter.com/ElUBJvW0vE
— Pfizer Inc. (@pfizer_news) July 13, 2020
15:02 IST, August 22nd 2020